NSE ScannerChemicals · Chemicals: Specialty · NSE: KRONOX · data 2026-10-31
Kronox Lab Sciences Limited
In plain words
Price: 18.2% below its 52-week high of ₹227.74.
Delivery: 37.6% of traded shares were kept for delivery over the last 10 sessions, against 49.3% over the last 60.
Latest results: a net profit of ₹7 cr for the quarter ended Dec 2025 (+0.9% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹105 cr |
| Net profit (last 12 months) | ₹29 cr |
| Sales growth, 3 years (yearly) | 1.9% |
| Profit growth, 3 years (yearly) | 19.0% |
At a glance
Promoters 74.2%, pledged 0.0%, institutions 2.1%.
P/E 24.2, dividend yield 0.3%. Price relative to earnings and book value (low is cheaper, not better).
ROE 26.8%, ROCE 31.6%, operating margin 31.4%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 19.0% and sales growth 1.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (26.8%).
- Healthy operating margin (31.4%).
- Profit grew 19.0% a year over 3 years.
- Slow sales growth (1.9% a year over 3 years).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY26)
KRONOX Q3 FY26 results (standalone figures, as filed on NSE).
Revenue was ₹25.27 crore, up 5.2% YoY.
Net profit was ₹6.59 crore, up 0.9% YoY.
Operating margin was 31.7% (34.8% a year ago).
EPS was ₹1.79, up 1.1% YoY.
KRONOX के Q3 FY26 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹25.27 करोड़; पिछले साल की तुलना में 5.2% की बढ़त।
शुद्ध मुनाफ़ा: ₹6.59 करोड़; पिछले साल की तुलना में 0.9% की बढ़त।
ऑपरेटिंग मार्जिन: 31.7% (एक साल पहले 34.8%)।
EPS: ₹1.79; पिछले साल की तुलना में 1.1% की बढ़त।
KRONOXના Q3 FY26 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹25.27 કરોડ; ગયા વર્ષની સરખામણીએ 5.2% વધારો.
ચોખ્ખો નફો: ₹6.59 કરોડ; ગયા વર્ષની સરખામણીએ 0.9% વધારો.
ઓપરેટિંગ માર્જિન: 31.7% (એક વર્ષ પહેલાં 34.8%).
EPS: ₹1.79; ગયા વર્ષની સરખામણીએ 1.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Dividend ● Results
- 6 Oct 26Insider SAST disclosure: Indo Borax & Chemicals Limited acquired 2,38,44,000 shares +7.0% next session
- 9 Sept 26Dividend Dividend ₹0.5 (ex-date) -1.7% next session
- 14 Feb 26Results Q3 FY26 results: profit +0.9% YoY -0.5% next session
- 11 Aug 25Results Q1 FY26 results: net profit ₹6.3 cr -5.9% next session
- 8 Aug 25Dividend Dividend ₹0.5 (ex-date) -4.5% next session
- 22 May 25Results Q4 FY25 results: net profit ₹6.3 cr -0.7% next session
- 31 Jan 25Results Q3 FY25 results: net profit ₹6.5 cr 0.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2025 | ₹25 cr | ₹7 cr | +0.9% | 31.7% | 1.79 |
| Jun 2025 | ₹24 cr | ₹6 cr | — | 32.8% | 1.7 |
| Mar 2025 | ₹26 cr | ₹6 cr | — | 29.7% | 1.72 |
| Dec 2024 | ₹24 cr | ₹7 cr | — | 34.8% | 1.77 |
Shareholding trend
| Holder | Jun 2026 | Sept 2025 |
|---|---|---|
| Promoters | 74.21% | 74.21% |
| Foreign institutions (FII) | 0.04% | 0.03% |
| Domestic institutions (DII) | 2.07% | 1.93% |
| Mutual funds | — | — |
| Retail investors | 18.98% | 18.78% |
| Number of shareholders | 32,479 | 35,780 |
Common questions
What was Kronox Lab Sciences Limited's latest quarterly profit?
Kronox Lab Sciences Limited reported a net profit of ₹7 cr for the quarter ended Dec 2025 (+0.9% on the same quarter a year earlier), on revenue of ₹25 cr.
How much do promoters hold in Kronox Lab Sciences Limited?
Promoters held 74.21% of Kronox Lab Sciences Limited at the end of Jun 2026, with 0.00% of promoter shares pledged.
Is Kronox Lab Sciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Kronox Lab Sciences Limited's P/E ratio?
About 24.2, based on the last 12 months' earnings and a price of ₹186.26 (data 2026-10-31).
What is the 52-week high and low of Kronox Lab Sciences Limited?
The 52-week high is ₹227.74 and the 52-week low is ₹96.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Kronox Lab Sciences Limited | ₹186.26 | ₹698 cr | 24.2 | — | 26.8% | 31.6% | 0.01 | +22.8% |
| Kanoria Chemicals & Industries Ltd | ₹167.34 | ₹738 cr | 12.8 | — | 7.3% | 4.2% | 0.51 | +112.8% |
| Transpek Industry Limited | ₹1,221.1 | ₹690 cr | 17.5 | — | 6% | 6.2% | 0.1 | +7.5% |
| Sadhana Nitro Chem Limited | ₹2.25 | ₹682 cr | — | 1.5 | -23.5% | -13.9% | 0.25 | +14.6% |
| Chemcon Speciality Chemicals Ltd | ₹181.84 | ₹673 cr | 22.2 | 1.4 | 4.8% | 3.9% | 0.11 | -28.6% |
| Amal Ltd. | ₹532.65 | ₹660 cr | 22.1 | 4.7 | 20.4% | 23.5% | 0 | -30.1% |
Compare KRONOX with KANORICHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KRONOX in NSE Scanner →